Dog trainer warns against 'deadly' act almost EVERY owner does with their pets every day
Adam Spivey, the British founder of Southend Dog Training, warned pet parents against walking their dogs immediately after feeding them, describing it as 'one of the most dangerous things you can do' as a dog owner.
In a video that has since gone viral, Spivey explained that feeding your dog and then taking them for a walk can cause a life-threatening condition known as 'bloat'.
'It's so important that if you are going to feed your dog before a walk, you give them at least 45 minutes to an hour before doing any physical activities,' he said.
The expert clarified that gentle movement is fine, but 'properly exercising them' too soon is risky.
'You need to give time for that food to go down.'
Spivey added that not only is it safer to feed your dog after a walk, it also helps with appetite and fussiness.
'They're going to be more hungry after they've burned off some energy,' he said.
'It reduces the chance of them being fussy if you feed them after exercise.'
Veterinarians back the warning, with Cronulla Veterinary Clinic describing gastric dilatation-volvulus (GDV) - commonly known as bloat - as a fast-moving and often fatal condition.
According to the clinic, bloat occurs when a dog's stomach becomes distended with gas, fluid or food, placing pressure on nearby organs and arteries.
In severe cases, the stomach can twist, cutting off blood flow to major organs and causing shock.
'GDV develops without warning and can progress quickly,' the clinic explains.
'It's always an emergency, as every minute without treatment increases the risk of further damage and, ultimately, death.'
Dogs with deep chests - like Great Danes, German Shepherds, Pointers, Mastiffs, Rottweilers, Boxers, and Greyhounds - are most at risk.
However, the condition has been reported in nearly all breeds, including smaller dogs like Dachshunds, Shar Peis, and Basset Hounds.
Common triggers include eating too quickly, overeating, drinking a large amount of water in one go, raised food bowls, stress, genetics, and, critically, exercising after eating.
The warning has struck a chord with dog lovers online, many of whom shared heartbreaking stories in the comment section.
'I lost the most amazing dog to bloat. It is no joke. It happens unexpectedly. It is always an emergency and most dogs don't survive it. It is terrible' one person wrote.
Another dog owner said the advice had likely saved their pet.
'I saw a post about this three years ago when I had not long had my staffy. I'm so glad I saw it. I used to feed her and take her for a walk straight after. It sparked me to learn more about being a dog parent - I realised pretty quickly there was heaps I didn't know.'
Others are already taking precautions.
'We have three German Shepherds and anytime they eat, they have to wait at least one hour before walking or playing,' one user commented.
The takeaway? Hold off on the walkies after mealtime - your dog's life may depend on it.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Daily Mail
an hour ago
- Daily Mail
Father-of-two, 39, thought stomach pain was from 'dodgy sausage' at BBQ... but it was colon cancer - doctors gave him 'months to live'
The first sign something was wrong for Matt Eamer came just days after a family barbeque, celebrating his son's second birthday. The then 39-year-old father-of-two from Redhill, Surrey, dismissed the sudden 'spiky' stomach pain as food poisoning. 'I was speaking to work colleagues over the first week or two and thought I'd cooked a dodgy sausage,' he said. But his pain escalated quickly. After a rushed trip to A&E he was sent home with anti-nausea medication Buscopan, yet still felt dreadful. His wife Sarah, 41, a doula, took him to East Surrey Hospital where scans revealed a 'big blockage' in his large intestine. Surgeons removed two-thirds of his bowel in an emergency op. 'A few days later they confirmed it was cancer,' Matt said. The diagnosis was stage four bowel cancer. The disease had already spread to his liver and the lining of his abdomen, and further tests revealed a rare BRAF mutation which drives tumours to grow at speed. 'I can still remember the person's voice when she phoned and said, "the plan for your diagnosis has changed… we're talking months not years from a survival point of view",' Matt recalled of the events in September 2020. On his 40th birthday he was told standard chemotherapy had failed and surgeons found the cancer had advanced further. 'It was a very dramatic, movie-like point,' he said. 'It was a pivotal change. They said, "we've gone in, it's gone further, we're going to try these new drugs." My wife Sarah collapsed to the floor.' Matt began fortnightly Cetuximab infusions combined with four daily Encorafenib pills, new immunotherapy drugs approved just months earlier. Designed to buy only 'three to six months', they had a remarkable effect. Within six months, scans showed no trace of cancer. Five years on, he is still clear and continues treatment. 'Hitting five years with stage four is a rarity,' he said. 'You're not on your death bed but you're forced to think about how you spend your time.' In December 2024, he underwent a 14-hour surgery to remove cancerous tissue in his ribcage, followed by heated HIPEC chemotherapy. The disease had already spread to his liver and the lining of his abdomen, and further tests revealed a rare BRAF mutation which drives tumours to grow at speed. Again, scans showed 'things clear.' Matt, who runs his own design agency, continues working and raising his two children. 'The reality is younger people are able to deal with treatments better and live longer, better lives even if it is stage four,' he said. He adds: 'The reality is the 'bucket and spade things', the little moments. I spend more time looking at my kids' faces, taking them to a show or swimming in the sea — they are heightened. 'It means your ability to be present and focus upon what matters is heightened.' To mark five years since his diagnosis, Matt will join Sir Chris Hoy's charity cycle in Glasgow on September 7, raising funds for Bowel Cancer UK. 'It's marking a milestone in a meaningful, positive way,' he said. Bowel cancer, also known as colorectal cancer, is one of the most common cancers in both Britain and the United States. In the UK around 43,000 people are diagnosed every year, while in the US the figure is more than 150,000. It is the third most common cancer worldwide and the second leading cause of cancer deaths. In older age groups incidence is declining thanks to better screening and awareness, yet in younger people rates are rising sharply, a trend baffling doctors. In England cases among those aged 25 to 49 have surged by around 3.6 per cent per year, one of the steepest increases in Europe, while in America rates in under-50s have been rising by about 2.4 per cent annually over the past decade. Outcomes depend heavily on how early the disease is caught. In the UK one-year survival is around 97 per cent if picked up through screening, but just 49 per cent if discovered in an emergency admission, as was the case for Matt. In the US five-year survival is 92 per cent at stage one but only 13 per cent at stage four. Most people with a diagnosis as advanced as Matt's do not reach the five-year mark, making his story unusual. Risk factors include family history, inflammatory bowel disease, obesity, alcohol, smoking, and diets low in fibre and high in red or processed meats. Researchers are also examining the role of ultra-processed foods, though evidence remains inconclusive, and some studies point to gut bacteria toxins such as colibactin, found in food poisoning, as a possible trigger for early-onset cases. Screening programmes remain vital. In the US guidelines now recommend testing from age 45, while in the UK stool tests are currently offered from 56, with pilot schemes lowering the age to 50. Symptoms to watch for include persistent changes in bowel habits, blood in stools, unexplained weight loss, abdominal pain or bloating, and lumps in the abdomen. Doctors stress that catching the disease early saves lives. Patients diagnosed at stage one are several times more likely to survive long term than those at stage four. But as Matt's case shows, advances in treatment—from new targeted drugs to more effective surgery—are beginning to change what is possible, even in the most serious cases. For him, the experience has redefined life. 'The reality isn't bucket-list dolphins—it's the bucket and spade things,' he said.
The Independent
2 hours ago
- The Independent
Type 2 diabetes patients set for major shake-up in care
People with type 2 diabetes in England are to get the biggest shake up of care in a decade which could see them offered treatments, including jabs that aid weight-loss, sooner. The health service should move from a one-size-fits-all approach of starting everyone on the same medication, to more personalised care that aims to prevent complications like heart failure and heart attacks, according to new draft guidance from the National Institute for Health and Care Excellence (Nice). This includes making newer type 2 diabetes drugs, known as SGLT-2 inhibitors, a first-line treatment option in a move that could eventually help save tens of thousands of lives. SGLT-2 inhibitors, which include canagliflozin, dapagliflozin, empagliflozin, and ertugliflozin, are once-a-day tablets that reduce blood sugar levels by helping the kidneys remove glucose, which is passed from the body through urine. However, analysis by Nice found these drugs are under-prescribed. The new guidelines recommend patients who cannot tolerate metformin – the first-choice in type 2 diabetes medication – should start with an SGLT-2 inhibitor on its own. The decision comes after evidence suggested these drugs protect the heart and kidneys as well as controlling blood sugar, Nice said. It is estimated the change could save almost 22,000 lives once uptake reaches 90% of the population. Nice also suggests some groups of patients would also benefit from GLP-1 receptor agonists such as liraglutide or semaglutide sooner, rather than keeping them for the later stages of treatment. Semaglutide, sold under the brand name Ozempic, is licensed in the UK to treat type 2 diabetes, while its other brand – Wegovy – is also used by the NHS to help obese people lose weight. Professor Jonathan Benger, deputy chief executive and chief medical officer at Nice, said: 'This guidance means more people will be offered medicines where it is right to do so to reduce their future risk of ill health. 'This represents a significant evolution in how we approach type 2 diabetes treatment. 'We're moving beyond simply managing blood sugar to taking a holistic view of a person's health, particularly their cardiovascular and kidney health. 'The evidence shows that certain medicines can provide important cardiovascular benefits, and by recommending them as part of initial treatment, we could help prevent heart attacks, strokes and other serious complications before they occur. 'This is particularly important given that cardiovascular disease is the leading cause of death in people with type 2 diabetes.' Around 4.6 million people in the UK are living with diabetes, with nine in 10 of those having type 2. However, it is estimated that a further 1.3 million people may have undiagnosed type 2 diabetes. Nice analysed the records of 590,000 people and found SGLT-2 inhibitors are under-prescribed, particularly to women, older people, and black patients. Prof Benger added: 'The evidence from our analysis is clear. There are prescribing gaps that need to be addressed. 'The guideline update published today will help to increase equitable uptake of SGLT-2 inhibitors, which we know can prevent serious health complications.' Dr Waqaar Shah, chairman of the guideline committee, added: 'We know that SGLT-2 inhibitors are currently under-prescribed, and our health economics analysis shows that people living in the most deprived areas would particularly benefit from universal access to these treatments. 'These recommendations could help reduce health inequalities while providing better outcomes for everyone.' Elsewhere, the draft guidance suggests different treatments for diabetes patients with certain characteristics or health conditions. These include adults with cardiovascular disease, who should be offered a triple therapy including a GLP-1 receptor agonist. Meanwhile, adults diagnosed with type 2 diabetes before 40 should be offered dual therapy before a GLP-1 receptor agonist is considered, while patients with chronic kidney disease should have tailored recommendations based on their kidney function. A public consultation on the new Nice guidelines is open until October 2. Douglas Twenefour, head of clinical at Diabetes UK, said: 'This long-awaited announcement propels type 2 diabetes treatment into the 21st century. 'Boosting access to newer treatments will be transformative for people with type 2 diabetes, while ensuring the UK keeps pace with the global momentum in treating the condition. 'The majority of people with type 2 diabetes are not currently taking the most effective medication for them, putting them at risk of devastating diabetes-related complications. 'Diabetes is a leading cause of cardiovascular disease, and tailoring treatment based on individual risk could protect thousands against heart attacks and kidney disease. 'These guidelines could go a long way to easing the burden of living with this relentless condition, as well as helping to address inequities in type 2 diabetes treatments and outcomes.'
Daily Mail
2 hours ago
- Daily Mail
Devastating health impact of vaping revealed in major global study
Children who regularly vape are three times more likely to become smokers later in life, a bombshell report has claimed. Figures have long shown how the proportion of kids using e-cigarettes has exploded amid the decline of traditional smoking, with more than a third of 16 to 18-year-olds now regularly inhaling them. For comparison, less than one in ten were doing so a decade ago. But British researchers now believe the gadgets could pose a worse threat to children than thought. In the largest global review on vaping in young people to date, experts from the University of York and the London School of Hygiene and Tropical Medicine (LSHTM), found that vapers were also more likely to smoke more frequently and intensely. Regularly using e-cigs could also increase the odds of respiratory illness and substance abuse, the scientists said. However, other experts urged caution over the findings noting many of the studies assessed were merely observational and could not prove that vaping alone caused such health issues. In the research, the scientists analysed 56 reviews on 384 youth vaping studies. Of these, 21 looked at use of e-cigarettes among young people and later cigarette smoking. Writing in the journal Tobacco Control, the authors said the data available 'consistently indicated a significant association between e-cigarette use and later cigarette smoking in young people'. They said it was difficult to 'infer causality' from their review, but the 'repeated strong associations in prospective cohort studies are consistent with a causal relationship'. The analysis also suggested an increased risk among young people who vape of developing asthma or asthma exacerbation, they added. Other harmful outcomes linked to youth vaping included pneumonia, bronchitis, lower total sperm counts, dizziness, headaches and migraines. There was also a link identified between depression and suicidal thoughts among young vapers. Dr Su Golder, associate professor in health science at the University of York, said: 'The consistency in the evidence is striking. 'Across multiple studies, young people who use e-cigarettes are more likely to smoke in the future. These findings support stronger public health measures to protect teens from the risks associated with vaping.' Dr Greg Hartwell, clinical assistant professor at LSHTM, said: 'We found consistent evidence around transitions to smoking which of course, in turn, opens the door to the multitude of harms that conventional cigarettes bring. 'As the UK Government's chief medical officer states, marketing vapes to children is always unacceptable, and our review shows exactly why further restrictions on the tobacco industry, who control the vaping market, are so important.' Dr Rebecca Glover, senior author of the study, assistant professor at LSHTM, added: 'Vaping is having a detrimental impact on the health of young people globally and vaping appears to be a gateway to other substances. 'Our study provides the strongest evidence to date that young people globally face a serious range of physical and psychological harms from vaping and are at higher risk of transitioning to smoking.' But other experts today, who weren't involved in the research, labelled the findings 'overspeculation' and warned the studies analysed were observational or low quality. Professor Ann McNeill, an expert in tobacco addiction at King College London, said: 'It reported on 56 systematic reviews of which 53 were rated critically low or low quality, meaning authors should be extremely cautious before making any conclusions. 'The authors reported that the reviews found consistently that vaping was associated with subsequent smoking. 'This replicates the findings of many previous reviews and indeed research I have been involved in. 'However, the authors incorrectly state that this supports "a causal relationship". 'in other words that vaping causes smoking—the so-called 'gateway' effect. It is well-established that consistency does not mean causality.' Meanwhile, Dr Emma Beard, an associate professor in statistics and quantitative methods at University College London, said: 'The conclusion that vaping acts as a "gateway" is an overspeculation, especially when the paper notes that at a population level, smoking rates have generally fallen as vaping has risen. 'While protecting youth is vital, this review clearly shows the current evidence base on this topic has some significant weaknesses.' E-cigs allow people to inhale nicotine in a vapour—which is produced by heating a liquid, which typically contains propylene glycol, glycerine, flavourings, and other chemicals. Unlike traditional cigarettes, they do not contain tobacco, nor do they produce tar or carbon—two of the most dangerous elements. Nicotine's effect on the brain is well known—within 20 seconds of inhalation, it triggers the release of chemical messengers such as dopamine, associated with reward and pleasure. But it also increases heart rate and blood pressure and makes blood vessels constrict. This is because nicotine triggers the release of the hormone adrenaline. Despite NHS chiefs insisting it is safer than smoking, vaping is not risk-free. E-cigarettes can contain harmful toxins and their long-term effects remains a mystery. Experts are also concerned the high nicotine content might increase blood pressure and cause other heart problems. Last year, in world-first guidance setting out possible interventions to help people stop using tobacco products, the World Health Organization labelled the evidence around e-cigarettes as 'complex'. Vapes could not be recommended as way to stop smoking as too little is known about the harms and benefits, the UN agency said. In June, in a bid to tackle the surge in youth vaping, it was made illegal for businesses to sell or supply single-use vapes, such as Elf bars and Lost Mary, in shops and online. Only devices considered reusable—with a rechargeable battery and replaceable coil—are now allowed.
